Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19275155 | FORMULATIONS OF ANTI-INTERLEUKIN 1 RECEPTOR 1 ANTIBODIES | July 2025 | November 2025 | Allow | 4 | 1 | 0 | No | No |
| 19214841 | CATIONIC LIPIDS AND PREPARATION METHOD THEREOF | May 2025 | January 2026 | Allow | 8 | 0 | 0 | No | No |
| 19172351 | KISSPEPTIN RECEPTOR (KISS1R) TARGETED THERAPEUTICS AND USES THEREOF | April 2025 | August 2025 | Allow | 4 | 1 | 0 | No | No |
| 19056537 | STABLE RADIOPHARMACEUTICAL COMPOSITIONS AND USES THEREOF | February 2025 | August 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 19028880 | STABLE FORMULATIONS FOR RADIONUCLIDE COMPLEXES | January 2025 | December 2025 | Allow | 11 | 2 | 1 | Yes | No |
| 18899589 | COMPOSITIONS AND METHODS OF TREATING MELANOMA | September 2024 | January 2026 | Abandon | 15 | 2 | 0 | No | No |
| 18750073 | RADIOLABELED ANTI-PD-L1 ANTIBODIES FOR IMMUNO-PET IMAGING | June 2024 | August 2025 | Allow | 14 | 1 | 1 | No | No |
| 18662569 | METHODS FOR DETECTING CCR2 RECEPTORS | May 2024 | August 2025 | Allow | 16 | 1 | 1 | No | No |
| 18706375 | EPSILON-POLY-L-LYSINE-BASED DRUG CONJUGATE, INTERMEDIATE THEREOF, AND APPLICATION THEREOF | April 2024 | February 2026 | Abandon | 21 | 0 | 0 | No | No |
| 18621985 | LABELED OXYTOCIN AND METHOD OF MANUFACTURE AND USE | March 2024 | July 2025 | Allow | 15 | 1 | 0 | No | No |
| 18609743 | Composition containing a somatostatin analogue for radiopharmaceutical use | March 2024 | September 2025 | Abandon | 18 | 1 | 0 | No | No |
| 18606317 | CXCR4-TARGETED DIAGNOSTIC AND THERAPEUTIC AGENTS WITH REDUCED SPECIES SELECTIVITY | March 2024 | September 2025 | Abandon | 18 | 1 | 0 | No | No |
| 18424207 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | January 2024 | January 2026 | Allow | 24 | 2 | 1 | No | No |
| 18360859 | COMPOSITIONS AND METHODS FOR CANCER IMAGING AND RADIOTHERAPY | July 2023 | July 2025 | Allow | 23 | 2 | 0 | Yes | No |
| 18357073 | COMPOSITIONS COMPRISING ASCORBIC ACID AND AN IMAGING AGENT AND RELATED METHODS | July 2023 | October 2025 | Abandon | 27 | 1 | 0 | No | No |
| 18322854 | METHODS FOR DIAGNOSING AND MONITORING EOSINOPHILIC ESOPHAGITIS | May 2023 | March 2026 | Abandon | 34 | 2 | 0 | No | No |
| 18119070 | HER2 BINDERS | March 2023 | January 2026 | Allow | 35 | 2 | 0 | Yes | No |
| 18104037 | USES OF LABELED HSP90 INHIBITORS | January 2023 | December 2025 | Allow | 34 | 2 | 0 | No | No |
| 18070175 | High Specific Activity Preparation of F-18 Tetrafluoroborate | November 2022 | September 2025 | Abandon | 33 | 1 | 0 | No | No |
| 18053682 | PROTEASE-ACTIVATED CONTRAST AGENTS FOR IN VIVO IMAGING | November 2022 | June 2025 | Allow | 31 | 1 | 0 | No | No |
| 17952056 | AN INJECTABLE AND IN-SITU CROSSLINKING HYDROGEL FOR ENDOVASCULAR EMBOLIZATION | September 2022 | February 2026 | Allow | 40 | 2 | 1 | No | No |
| 17901299 | PHOTODYNAMIC THERAPY COMPOSITION | September 2022 | July 2025 | Allow | 34 | 2 | 0 | No | No |
| 17819180 | TARGETED PROTEIN CONTRAST AGENTS, METHODS OF MAKING, AND USES THEREOF | August 2022 | August 2025 | Allow | 36 | 2 | 0 | No | No |
| 17881350 | FREE PSA ANTIBODIES AS DIAGNOSTICS, PROGNOSTICS AND THERAPEUTICS FOR PROSTATE CANCER | August 2022 | March 2026 | Allow | 43 | 2 | 1 | No | No |
| 17811006 | COMPOUNDS HAVING RD TARGETING MOTIFS AND METHODS OF USE THEREOF | July 2022 | January 2026 | Abandon | 42 | 1 | 0 | No | No |
| 17782931 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR IL-17 | June 2022 | March 2026 | Abandon | 45 | 1 | 0 | No | No |
| 17782910 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR IL-17 | June 2022 | March 2026 | Abandon | 45 | 1 | 0 | No | No |
| 17756428 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MASTITIS | May 2022 | January 2026 | Abandon | 43 | 0 | 1 | No | No |
| 17779226 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EphA2 AND USES THEREOF | May 2022 | January 2026 | Abandon | 43 | 1 | 0 | No | No |
| 17739873 | CHOLECYSTOKININ B RECEPTOR TARGETING FOR IMAGING AND THERAPY | May 2022 | September 2025 | Allow | 40 | 2 | 0 | No | No |
| 17770315 | RADIOISOTOPE LABELED COMPOUND FOR IMAGING OR TREATMENT OF PROSTATE CANCER | April 2022 | September 2025 | Allow | 41 | 1 | 0 | No | No |
| 17770382 | PSMA-TARGETING IMAGING AGENTS | April 2022 | November 2025 | Allow | 43 | 2 | 0 | Yes | No |
| 17768711 | EPCAM BINDING FIBRONECTIN TYPE III DOMAINS | April 2022 | August 2025 | Allow | 40 | 1 | 0 | No | No |
| 17767847 | METHODS AND SYSTEMS USING PEPTIDES FOR TARGETING AND MAPPING HUMAN NERVES IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | April 2022 | October 2025 | Allow | 43 | 1 | 0 | No | No |
| 17766708 | PEPTIDE-NUCLEIC ACID COMPLEX HAVING BLOOD-BRAIN BARRIER PENETRATION ABILITY AND COMPOSITION COMPRISING SAME | April 2022 | November 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17712729 | PET IMAGING WITH PD-L1 BINDING POLYPEPTIDES | April 2022 | August 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17712930 | KRAS-SPECIFIC CYCLIC PEPTIDES, COMPOSITIONS, AND METHODS OF USING AND MAKING | April 2022 | November 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17697485 | POSITRON EMITTING RADIONUCLIDE LABELED PEPTIDES FOR HUMAN UPAR PET IMAGING | March 2022 | May 2025 | Allow | 38 | 2 | 0 | Yes | No |
| 17642668 | IRON(III) COMPLEXES HAVING NEW CONTRAST AGENT PROPERTIES, FOR MAGNETIC RESONANCE IMAGING | March 2022 | August 2025 | Allow | 41 | 1 | 0 | No | No |
| 17638939 | ORAL COMPOSITION FOR IMPROVING MEMORY-LEARNING ABILITY | February 2022 | October 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17638424 | REAGENT FOR MEASURING OXYGEN CONCENTRATION IN CELL AND TISSUE | February 2022 | August 2025 | Allow | 41 | 1 | 0 | Yes | No |
| 17634487 | PHOTODYNAMIC THERAPY METHOD MEDIATED BY CHLORIN E6 PHOTOSENSITIZER COMPOSITE FOR TREATING AND PREVENTING OBESITY | February 2022 | October 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17590549 | SYNTHESIS METHODS AND COMPOSITIONS OF LOW INTERMEDIATE AND LOW DICHELATE INTERMEDIATE CONTRAST AGENTS | February 2022 | March 2026 | Allow | 49 | 2 | 1 | Yes | No |
| 17631738 | METHOD FOR TREATING ALZHEIMER'S DISEASE BY REGULATING INTESTINAL MICROORGANISMS | January 2022 | October 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17630728 | H2O2-RESPONSIVE CROSSLINKING NEAR-INFRARED MOLECULAR PROBE FOR TUMOR MICROENVIRONMENT AND USE THEREFOR | January 2022 | October 2025 | Allow | 44 | 2 | 1 | No | No |
| 17629258 | TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | January 2022 | October 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17625551 | ANTIBODIES TO HUMAN PROGRAMMED DEATH RECEPTOR PD-1 | January 2022 | July 2025 | Allow | 42 | 1 | 1 | No | No |
| 17625224 | NOVEL MOLECULAR TOOLS TO VISUALIZE AND TARGET THE CARDIAC CONDUCTION SYSTEM (CCS) | January 2022 | January 2026 | Allow | 48 | 2 | 1 | Yes | No |
| 17625139 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | January 2022 | June 2025 | Allow | 41 | 1 | 0 | No | No |
| 17624112 | RENAL TARGETING-TYPE DRUG DELIVERY CARRIER HAVING EXCELLENT BIODEGRABILITY | December 2021 | October 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17596802 | FOAMABLE COMPOSITION FOR USE IN SURGICAL DIAGNOSTIC PROCEDURES | December 2021 | January 2026 | Allow | 49 | 2 | 1 | Yes | No |
| 17595751 | RK POLYPEPTIDE RADIOPHARMACEUTICAL TARGETING HER2 AND PREPARATION METHOD THEREOF | November 2021 | November 2025 | Allow | 48 | 1 | 1 | No | No |
| 17612849 | ANTIBODY CONJUGATE AND APPLICATION OF PHARMACEUTICAL COMPOSITION THEREOF | November 2021 | December 2025 | Abandon | 48 | 1 | 1 | No | No |
| 17531485 | COMPOSITIONS AND METHODS OF TREATING MELANOMA | November 2021 | January 2026 | Abandon | 50 | 1 | 1 | No | No |
| 17524673 | THERAPY FOR SUBARACHNOID HEMORRHAGE AND ISCHEMIA | November 2021 | October 2025 | Abandon | 47 | 0 | 1 | No | No |
| 17507400 | COMPOSITIONS AND METHODS OF TREATING MELANOMA | October 2021 | October 2022 | Allow | 12 | 1 | 0 | No | No |
| 17505037 | CONTROLLED AND PRECISE TREATMENT OF CARDIAC TISSUES | October 2021 | January 2026 | Allow | 51 | 1 | 1 | No | No |
| 17424104 | PEPTIDE PET/SPECT PROBES SPECIFIC TO ONCOPROTEINS IN TUMOR EXTRACELLULAR MATRIX | July 2021 | November 2025 | Allow | 52 | 1 | 1 | No | No |
| 17376670 | COMPOUNDS AND METHODS FOR THE DETECTION OF TRPV-6 CANCERS AND DRUG DELIVERY | July 2021 | July 2025 | Allow | 48 | 1 | 1 | No | No |
| 17144067 | 177-Lu LABELED PEPTIDE FOR SITE-SPECIFIC uPAR-TARGETING | January 2021 | January 2026 | Allow | 60 | 4 | 0 | Yes | No |
| 17131324 | BI-TERMINAL PEGYLATED INTEGRIN-BINDING PEPTIDES AND METHODS OF USE THEREOF | December 2020 | June 2022 | Allow | 18 | 1 | 0 | No | No |
| 17127618 | RADIOLABELED ANTI-LAG3 ANTIBODIES FOR IMMUNO-PET IMAGING | December 2020 | May 2022 | Allow | 17 | 1 | 0 | Yes | No |
| 17117697 | HER2 BINDERS | December 2020 | December 2022 | Allow | 24 | 2 | 0 | Yes | Yes |
| 16973349 | COMPOUNDS FOR USE AS IRON (III) MRI CONTRAST AGENTS CONTAINING ANIONIC PENDENTS AND ANCILLARY GROUPS | December 2020 | January 2022 | Allow | 13 | 2 | 0 | Yes | No |
| 17063158 | TOLL-LIKE RECEPTOR 2 LIGANDS AND METHODS OF MAKING AND USING THEREOF | October 2020 | May 2022 | Allow | 19 | 1 | 0 | No | No |
| 17017135 | COMPOUNDS HAVING RD TARGETING MOTIFS AND METHODS OF USE THEREOF | September 2020 | May 2022 | Allow | 20 | 1 | 0 | Yes | No |
| 17015633 | TARGETED PROTEIN CONTRAST AGENTS, METHODS OF MAKING, AND USES THEREOF | September 2020 | April 2022 | Allow | 19 | 1 | 0 | Yes | No |
| 17015571 | TARGETED PROTEIN CONTRAST AGENTS, METHODS OF MAKING, AND USES THEREOF | September 2020 | April 2022 | Allow | 19 | 1 | 0 | No | No |
| 16969902 | NON-AGGREGATING HEPTAMETHINE CYANINE FLUOROPHORES FOR IN VIVO IMAGING | August 2020 | November 2020 | Allow | 3 | 0 | 0 | Yes | No |
| 16942537 | CHOLECYSTOKININ B RECEPTOR TARGETING FOR IMAGING AND THERAPY | July 2020 | February 2022 | Allow | 19 | 1 | 0 | No | No |
| 16934881 | USES OF LABELED HSP90 INHIBITORS | July 2020 | October 2022 | Allow | 27 | 2 | 1 | Yes | No |
| 16925105 | AMYLOID-BINDING COMPOUNDS AND METHODS OF USE THEREOF | July 2020 | March 2026 | Allow | 60 | 3 | 1 | No | Yes |
| 16916838 | ANTI-NUCLEOLIN AGENT-CONJUGATED NANOPARTICLES AS RADIO-SENSITIZERS AND MRI AND/OR X-RAY CONTRAST AGENTS | June 2020 | October 2022 | Abandon | 28 | 1 | 1 | No | No |
| 16915894 | RADIOLABELED ANTI-PD-L1 ANTIBODIES FOR IMMUNO-PET IMAGING | June 2020 | March 2022 | Abandon | 21 | 1 | 0 | No | No |
| 16957534 | METHODS FOR PREVENTING AND/OR TREATING BONE LOSS CONDITIONS BY MODULATING IRISIN | June 2020 | August 2025 | Abandon | 60 | 3 | 1 | No | No |
| 16908204 | CYCLIC PEPTIDES AS PROTEIN TARGETING AGENTS | June 2020 | February 2022 | Allow | 20 | 4 | 1 | Yes | No |
| 16900451 | CRYPTATE COMPOUNDS | June 2020 | August 2022 | Allow | 26 | 1 | 1 | Yes | No |
| 16900335 | CRYPTATE COMPOUNDS | June 2020 | August 2022 | Allow | 26 | 2 | 0 | No | No |
| 16897894 | METHOD FOR LABELING RADIOISOTOPE, RADIOLABELING COMPOUNDS USING QUINONE COMPOUND AND KIT COMPRISING THE SAME FOR LABELING RADIOISOTOPE | June 2020 | July 2022 | Allow | 25 | 2 | 1 | Yes | No |
| 16770180 | RADIOLABELED PROGASTRIN IN CANCER DIAGNOSIS | June 2020 | November 2022 | Abandon | 30 | 2 | 1 | No | No |
| 16880791 | THROMBUS IMAGING APTAMERS AND METHODS OF USING SAME | May 2020 | September 2022 | Allow | 28 | 2 | 1 | No | No |
| 16870776 | POSITRON EMITTING RADIONUCLIDE LABELED PEPTIDES FOR HUMAN UPAR PET IMAGING | May 2020 | December 2021 | Allow | 19 | 1 | 0 | No | No |
| 16758081 | RADIOACTIVE ANTITUMOR AGENT | April 2020 | September 2025 | Allow | 60 | 4 | 1 | Yes | Yes |
| 16845372 | HSP90-TARGETED INFLAMMATION AND INFECTION IMAGING AND THERAPY | April 2020 | March 2021 | Allow | 11 | 2 | 0 | Yes | No |
| 16648703 | METAL COMPLEX FORMING COMPOUND, METAL COMPLEX COMPOUND FORMED THEREOF, RADIOACTIVE DRUG CONTAINING THE METAL COMPLEX COMPOUND, AND METHOD OF USING AND PREPARING THE METAL COMPLEX COMPOUND | March 2020 | July 2021 | Allow | 15 | 2 | 0 | Yes | No |
| 16815760 | METHODS AND COMPOSITIONS FOR EFFICIENT DELIVERY THROUGH MULTIPLE BIO BARRIERS | March 2020 | June 2022 | Abandon | 27 | 0 | 1 | No | No |
| 16792142 | PROTEASE-ACTIVATED CONTRAST AGENTS FOR IN VIVO IMAGING | February 2020 | February 2023 | Abandon | 36 | 2 | 1 | No | No |
| 16790407 | Cleavable Lipids | February 2020 | September 2021 | Allow | 19 | 1 | 0 | Yes | No |
| 16632228 | PEPTIDE AMIDE COMPOUND AND PREPARATION METHOD AND MEDICAL USE THEREOF | January 2020 | January 2021 | Allow | 12 | 2 | 0 | No | No |
| 16628068 | DOTA-HAPTEN COMPOSITIONS FOR ANTI-DOTA/ANTI-TUMOR ANTIGEN BISPECIFIC ANTIBODY PRETARGETED RADIOIMMUNOTHERAPY | January 2020 | September 2022 | Allow | 32 | 1 | 0 | Yes | No |
| 16728510 | LABELLED SILICA-BASED NANOMATERIAL WITH ENHANCED PROPERTIES AND USES THEREOF | December 2019 | March 2022 | Abandon | 26 | 1 | 1 | No | No |
| 16626645 | REINFORCED MACROCYCLIC LIGANDS, COMPLEXES THEREOF, AND USES OF SAME | December 2019 | August 2021 | Allow | 20 | 1 | 0 | No | No |
| 16725602 | CELL IMPERMEABLE COELENTERAZINE ANALOGUES | December 2019 | August 2021 | Allow | 20 | 1 | 0 | Yes | No |
| 16625054 | Fibroblast Growth Factor Receptor 2-Specific Peptide Reagents and Methods | December 2019 | September 2021 | Allow | 21 | 0 | 0 | No | No |
| 16713468 | NOVEL DUAL TARGETING LIGAND FOR CANCER DIAGNOSIS AND TREATMENT | December 2019 | June 2021 | Allow | 19 | 1 | 0 | No | No |
| 16708804 | SYSTEMS AND METHODS FOR TARGETED IMAGING AND ABLATION OF CARDIAC CELLS | December 2019 | March 2022 | Allow | 27 | 2 | 1 | Yes | No |
| 16621173 | RENAL-HOMING PEPTIDE CONJUGATES AND METHODS OF USE THEREOF | December 2019 | March 2022 | Allow | 27 | 1 | 0 | No | No |
| 16704955 | CHLOROTOXIN CONJUGATES AND METHODS OF USE THEREOF | December 2019 | February 2023 | Abandon | 38 | 7 | 0 | No | No |
| 16699455 | ENHANCED TARGETED DELIVERY OF THERAPEUTIC AGENTS | November 2019 | February 2023 | Abandon | 38 | 2 | 1 | No | No |
| 16615514 | Anti-Warburg Nanoparticles - A matrix metalloprotease activatable conjugate to inhibit glioblastoma proliferation | November 2019 | June 2022 | Abandon | 30 | 0 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner JONES, DAMERON LEVEST.
With a 26.1% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 23.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner JONES, DAMERON LEVEST works in Art Unit 1618 and has examined 1,370 patent applications in our dataset. With an allowance rate of 61.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 38 months.
Examiner JONES, DAMERON LEVEST's allowance rate of 61.4% places them in the 21% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by JONES, DAMERON LEVEST receive 2.14 office actions before reaching final disposition. This places the examiner in the 58% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by JONES, DAMERON LEVEST is 38 months. This places the examiner in the 28% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +34.0% benefit to allowance rate for applications examined by JONES, DAMERON LEVEST. This interview benefit is in the 82% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 23.0% of applications are subsequently allowed. This success rate is in the 31% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 46.1% of cases where such amendments are filed. This entry rate is in the 70% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 91.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 68% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 73.9% of appeals filed. This is in the 62% percentile among all examiners. Of these withdrawals, 64.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 55.5% are granted (fully or in part). This grant rate is in the 57% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 8.9% of allowed cases (in the 92% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 4.3% of allowed cases (in the 78% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.